3 Biotech

1. WANG Y, An S, Min Y
   Crocin-coated zinc-alginate-PEG nanocomposite induces ROS-mediated apoptosis via PI3K/Akt/mTOR suppression in bladder cancer cells.
   3 Biotech. 2026;16:248.
   

   >> Share

   
   

   
   ACS Appl Bio Mater

2. JIAO B, Xu Y, Wang X, Zhang H, et al
   Biomimetic Nanoparticles Based on Tumor Cell Membrane Co-loaded with Vitamin E and Doxorubicin for Targeted Synergistic Treatment of Bladder Cancer.
   ACS Appl Bio Mater. 2026 Jun 1. doi: 10.1021/acsabm.6c00552.
   

   >> Share

   
   

   
   Ann Surg Oncol

3. ZHANG Y, Li R, Shi H, Zhao A, et al
   ASO Author Reflections: Benchmarking Large Language Models for Bladder Cancer: Comparative Knowledge Retrieval and Clinical Reasoning of DeepSeek and ChatGPT.
   Ann Surg Oncol. 2026 Jun 1. doi: 10.1245/s10434-026-19845.
   

   >> Share

   
   

   
   bioRxiv

4. YIM K, Vergara M, Lee J, Reardon B, et al
   Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.
   bioRxiv [Preprint]. 2026 May 18:2026.05.10.724123.
   

   >> Share

   
   
5. FINI MS, Alley JR, Vensko SP, Karthikeyan D, et al
   Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy.
   bioRxiv [Preprint]. 2026 May 27:2026.05.20.726664.
   

   >> Share

   
   

   
   Bladder Cancer

6. BOYNE A, Anderson RC, Liu D, Varghese B, et al
   Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis.
   Bladder Cancer. 2026;12:23523735261455396.
   

   >> Share

   
   

   
   BMJ Case Rep

7. NIKOLAUS Y
   p40-positive metastatic urothelial carcinoma mimicking primary pulmonary squamous cell carcinoma on limited lung biopsy.
   BMJ Case Rep. 2026;19:e272914.
   

   >> Share

   
   

   
   Br J Cancer

8. MURRAY BO, Gao J, Pasquina-Lemonche L, Swarbrick K, et al
   An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.
   Br J Cancer. 2026 Jun 2. doi: 10.1038/s41416-026-03476.
   

   >> Share

   
   

   
   Cancer Cytopathol

9. CHEN L, Cao X, Lu Z, Liu L, et al
   Artificial intelligence-assisted urine cytology based on the Paris System for Reporting Urothelial Carcinoma.
   Cancer Cytopathol. 2026;134:e70120.
   

   >> Share

   
   

   
   Cancer Res

10. ROELS J, Ghaedi H, Kancherla J, Yang Y, et al
    The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1-Resistant Cancer.
    Cancer Res. 2026;86:2592-2605.
    

    >> Share

    
    

    
    Cell Death Differ

11. LIU Z, Yao Z, Hou Y, Liu Z, et al
    LGALS1-CD276 Paracrine axis between tumor and endothelial cells promotes tumor angiogenesis and progression in bladder cancer.
    Cell Death Differ. 2026 Jun 2. doi: 10.1038/s41418-026-01777.
    

    >> Share

    
    

    
    Cell Signal

12. LUO Y, Ma J, Wang C, Xiong W, et al
    ELK1-YBX1 signaling promotes cisplatin resistance via ferroptosis adaptation in bladder cancer.
    Cell Signal. 2026 Jun 1:112633. doi: 10.1016/j.cellsig.2026.112633.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

13. DIAZ GM, Isali I, Davis L, Wang B, et al
    Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer.
    Clin Genitourin Cancer. 2026 May 6:102578. doi: 10.1016/j.clgc.2026.102578.
    

    >> Share

    
    
14. YUAN H, Wang T, Peng P, Xu Z, et al
    Corrigendum to "Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment" [Clinical Genitourinary Cancer 22/2 (2024) 569-579.e1].
    Clin Genitourin Cancer. 2026 Jun 4:102584. doi: 10.1016/j.clgc.2026.102584.
    

    >> Share

    
    

    
    Clin Nephrol

15. HUANG J, Luo H, Du C, Zhai Q, et al
    Antibody-drug conjugate therapy in a renal transplant patient with bladder cancer: A case report.
    Clin Nephrol. 2026 Jun 3. doi: 10.5414/CN111972.
    

    >> Share

    
    

    
    Comput Methods Programs Biomed

16. FU L, Huang B, Shi L, Geng Y, et al
    DS-MTNet: A dual-stream multi-task network for histopathology localization and histologic risk stratification from small biopsy specimens of bladder cancer.
    Comput Methods Programs Biomed. 2026;284:109464.
    

    >> Share

    
    

    
    Diagn Cytopathol

17. GUPTA A, Chandra S, Verma T, Gupta A, et al
    The Paris System for Urine Cytology: Prospective Assessment of Reproducibility, Diagnostic Accuracy, and Malignancy Risk.
    Diagn Cytopathol. 2026;54:506-518.
    

    >> Share

    
    

    
    Eur Urol Oncol

18. MACDONALD LP, Kypriotakis G, Karam-Hage M, Minnix JA, et al
    Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer.
    Eur Urol Oncol. 2026 Jun 3:S2588-9311(26)00131-8. doi: 10.1016/j.euo.2026.
    

    >> Share

    
    

    
    Exp Mol Med

19. HUANG Z, Yan Y, Wang X, Li H, et al
    Tumor-derived WNT7A reprograms pulmonary fibroblasts to remodel the metastatic niche and promote bladder cancer lung metastasis.
    Exp Mol Med. 2026 Jun 3. doi: 10.1038/s12276-026-01735.
    

    >> Share

    
    

    
    Front Biosci (Landmark Ed)

20. ABOU CHAKRA M, Duquesne I, O'Donnell MA
    Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.
    Front Biosci (Landmark Ed). 2026;31:47606.
    

    >> Share

    
    

    
    Front Immunol

21. YANG J, You Z, Mo H, Pu J, et al
    Identification of succinylation-related genes in bladder cancer: integration of single-cell and transcriptomic data.
    Front Immunol. 2026;17:1797389.
    

    >> Share

    
    

    
    Front Public Health

22. YILMAZ B, Ataman M, Tuna A
    Detection of microplastics in bladder wash fluid obtained after cystoscopy in patients diagnosed with bladder cancer.
    Front Public Health. 2026;14:1812477.
    

    >> Share

    
    

    
    Indian J Surg Oncol

23. SELVARAJU A, Dwivedi DK, Patbamniya NK, Kumar M, et al
    Multiparametric MRI Radiomics for the Prediction of Histologic Grade in Bladder Cancer.
    Indian J Surg Oncol. 2026;17:1057-1064.
    

    >> Share

    
    
24. FERNANDES C, Brito C, Ferreira C, Botelho F, et al
    Ensuring Timely Detection of Bladder Cancer: The Role of a Screening for Haematuria Consultations.
    Indian J Surg Oncol. 2026;17:964-969.
    

    >> Share

    
    

    
    Int Immunopharmacol

25. YANG H, Zhou C, Zhou Z, Zhang F, et al
    YBX1 takes actions on triggering M2-like polarization of macrophages and stabilizing CXCL8 mRNA to exhibit its metastatic potential in bladder cancer.
    Int Immunopharmacol. 2026;184:116911.
    

    >> Share

    
    

    
    Int J Clin Exp Pathol

26. LIU J, Li B, Hou R, Sun J, et al
    A five-gene mitochondria-associated prognostic signature for bladder cancer.
    Int J Clin Exp Pathol. 2026;19:192-208.
    

    >> Share

    
    

    
    Int J Urol

27. NISHIMURA N, Miyake M, Iwao T, Oda Y, et al
    Sarcopenia Weakens the Benefit of Bacillus Calmette-Guerin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study.
    Int J Urol. 2026;33:e70526.
    

    >> Share

    
    

    
    J Clin Invest

28. MACH KE, Kornberg Z, Shkolyar E, Long J, et al
    Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance.
    J Clin Invest. 2026;136:e203094.
    

    >> Share

    
    

    
    J Clin Oncol

29. NECCHI A, de Jong JJ, Maiorano BA, Proudfoot JA, et al
    Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.
    J Clin Oncol. 2026 May 31:JCO2600142. doi: 10.1200/JCO-26-00142.
    

    >> Share

    
    

    
    J Intern Med

30. HANSEN MS, Dyrskjot L, Heide-Jorgensen U, Jensen JB, et al
    Aspirin or non-steroidal anti-inflammatory drug initiation and subsequent bladder cancer evaluation.
    J Intern Med. 2026 Jun 1. doi: 10.1111/joim.70115.
    

    >> Share

    
    

    
    J Urol

31. PRASAD S
    Reply: UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results from the Phase 3 ENVISION Trial.
    J Urol. 2026 Jun 2:101097JU0000000000005128. doi: 10.1097/JU.0000000000005128.
    

    >> Share

    
    

    
    JAMA Netw Open

32. ZHANG W, Wu H, Wang L, Xu H, et al
    Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    JAMA Netw Open. 2026;9:e2614764.
    

    >> Share

    
    

    
    Jpn J Clin Oncol

33. ICHIYAMA T, Narita T, Sekine Y, Shinohara M, et al
    Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients.
    Jpn J Clin Oncol. 2026 May 31:hyag087. doi: 10.1093.
    

    >> Share

    
    

    
    Nanomedicine (Lond)

34. NARAYAN A, Leibrandt RC, Lee JS, Dall'Era MA, et al
    A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.
    Nanomedicine (Lond). 2026 Jun 1:1-6. doi: 10.1080/17435889.2026.2674162.
    

    >> Share

    
    

    
    Oncotarget

35. ZHANG XJ, Yu HY, Cai YJ, Ke M, et al
    Retraction: Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway.
    Oncotarget. 2026;17:193-194.
    

    >> Share

    
    

    
    Pharmacol Res Nat Prod

36. BOLT MJ, Oceguera J, Tostado AR, Candler CD, et al
    A phenotypic screen identifies xanthohumol and other flavonoids as killers of bladder cancer.
    Pharmacol Res Nat Prod. 2025;7:100236.
    

    >> Share

    
    

    
    Res Sq

37. PALMBOS P, Kelleher A, Henderson M, Broses L, et al
    TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.
    Res Sq [Preprint]. 2026 May 20:rs.3.rs-9214925. doi: 10.21203/rs.3.rs-9214925.
    

    >> Share

    
    

    
    Sci Rep

38. PINTON P, Kawano H, Patschan O, Ravi A, et al
    A machine-learning approach to predict additional treatment after Bacillus Calmette-Guerin induction in non-muscle-invasive bladder cancer.
    Sci Rep. 2026 Jun 2. doi: 10.1038/s41598-026-55917.
    

    >> Share

    
    

    
    Theranostics

39. BELLMUNT J, Xie Y, Juanpere N, Munoz MG, et al
    Epigenetic subtypes of high-grade T1 bladder cancer reveal intra-tumor heterogeneity and distinct interactions with tumor microenvironment.
    Theranostics. 2026;16:6892-6910.
    

    >> Share

    
    
40. HE Y, Fang Z, Zhang J, Wei Q, et al
    Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy.
    Theranostics. 2026;16:6827-6842.
    

    >> Share

    
    

    
    Urol Oncol

41. KOHLER J, Buck L, Schliesser P, Weische O, et al
    Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients.
    Urol Oncol. 2026;44:92-100.
    

    >> Share

    
    
42. MUNK L, Kumarasegaram V, Hyldgaard JM, Jensen JB, et al
    Collecting electronic patient-reported outcomes via smartphone text messages in a bladder cancer RCT: A feasibility study.
    Urol Oncol. 2026;44:101-107.
    

    >> Share

    
    

    
    Vet Radiol Ultrasound

43. GUTTI JR, Clarke DM, Saba C, Nagata K, et al
    Incorporating Hypofractionated Radiotherapy Improves Management of Canine Urothelial Carcinoma: A Retrospective Study.
    Vet Radiol Ultrasound. 2026;67:e70196.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share